Trials / Recruiting
RecruitingNCT07230353
A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- Sponsor
- Xencor, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.
Detailed description
This is a Phase 1b study to determine the safety, tolerability, pharmacokinetic (PK), and pharmacodynamics (PD), and immunogenicity of plamotamab in adult participants with moderately to severely active RA. This is an open label dose optimization trial with approximately 68 participants assigned to different dose escalation cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Plamotamab | Biological |
Timeline
- Start date
- 2025-10-21
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
- First posted
- 2025-11-17
- Last updated
- 2026-04-14
Locations
3 sites across 3 countries: Georgia, Moldova, New Zealand
Source: ClinicalTrials.gov record NCT07230353. Inclusion in this directory is not an endorsement.